From: Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas
Factor | CGGA RNA-seq set | |||||
---|---|---|---|---|---|---|
Univariate | Multivariate | |||||
P | HR | 95% CI | P | HR | 95% CI | |
TOX | ||||||
 High vs. low | < 0.001 | 2.34 | 1.95–2.82 | < 0.001 | 1.44 | 1.18–1.76 |
Age | ||||||
 Increasing years | < 0.001 | 1.03 | 1.02–1.04 | 0.044 | 1.01 | 1.00–1.02 |
Gender | ||||||
 Male vs. female | 0.823 | 1.02 | 0.85–1.22 | 0.518 | 0.98 | 0.82–1.17 |
WHO grade | ||||||
Grade III vs. II | < 0.001 | 3.01 | 2.26–4.00 | < 0.001 | 2.90 | 2.17–3.86 |
 Grade IV vs. II | < 0.001 | 8.53 | 6.40–11.01 | < 0.001 | 5.22 | 3.88–7.02 |
1p19q status | ||||||
 Codel vs. non-codel | < 0.001 | 4.41 | 3.26–5.97 | < 0.001 | 2.56 | 1.85–3.55 |
IDH status | ||||||
Mutation vs. wild-type | < 0.001 | 3.12 | 2.59–3.75 | 0.023 | 1.23 | 0.99–1.54 |